Role of interleukin 10 in specific immunotherapy.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Journal of Clinical Investigation

• Publication date

  1998-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1172/JCI2250PMID 9649562PMCID PMC509070
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Igg subclass-restricted immune responses to allergens

  2004cited by this paper
• Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom.

  1998cited by this paper
• A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis

  1997cited by this paper
• The intensity of T cell receptor engagement determines the cytokine pattern of human allergen‐specific T helper cells

  1997cited by this paper
• Defective TCR stimulation in anergized type 2 T helper cells correlates with abrogated p56(lck) and ZAP-70 tyrosine kinase activities.

  1997cited by this paper
• Skin-homing, CLA+ memory T cells are activated in atopic dermatitis and regulate IgE by an IL-13-dominated cytokine pattern: IgG4 counter-regulation by CLA- memory T cells.

  1997cited by this paper
• Glucocorticoids inhibit human antigen‐specific and enhance total IgE and IgG4 production due to differential effects on T and B cells in vitro

  1997cited by this paper
• Insect venom immunotherapy induces interleukin‐10 production and a Th2‐to‐Th1 shift, and changes surface marker expression in venom‐allergic subjects

  1997cited by this paper
• Induction and differential regulation of bee venom phospholipase A2-specific human IgE and IgG4 antibodies in vitro requires allergen-specific and nonspecific activation of T and B cells.

  1997influential reference
• CD40 expression by human peripheral blood eosinophils.

  1996cited by this paper
• Influence of bee venom immunotherapy on degranulation and leukotriene generation in human blood basophils

  1996cited by this paper
• Modulation by IL-10 of antigen-induced IL-5 generation, and CD4+ T lymphocyte and eosinophil infiltration into the mouse peritoneal cavity.

  1996cited by this paper
• Interleukin (IL)-10 inhibits long-term IL-6 production but not preformed mediator release from rat peritoneal mast cells.

  1996cited by this paper
• Interleukin‐10 inhibits cytokine generation from mast cells

  1996cited by this paper
• Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro.

  1996influential reference
• Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures.

  1995cited by this paper
• Interleukin-10 inhibits antigen-induced cellular recruitment into the airways of sensitized mice.

  1995cited by this paper
• Type I skin reactivity to native and recombinant phospholipase A2 from honeybee venom is similar.

  1995cited by this paper
• Interleukin 4 production by CD4+ T cells from allergic individuals is modulated by antigen concentration and antigen-presenting cell type

  1995cited by this paper
• Detection of intracytoplasmic cytokine using flow cytometry and directly conjugated anti-cytokine antibodies.

  1995cited by this paper
• High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells

  1994cited by this paper
• Maintenance of clonal anergy by endogenously produced IL-10.

  1994cited by this paper
• Human monoclonal or polyclonal antibodies recognize predominantly discontinuous epitopes on bee venom phospholipase A2.

  1994cited by this paper
• Interleukin 10 inhibits lipopolysaccharide-induced survival and cytokine production by human peripheral blood eosinophils

  1994cited by this paper
• B7/CD28-dependent IL-5 production by human resting T cells is inhibited by IL-10.

  1994cited by this paper
• Induction of hapten-specific tolerance by interleukin 10 in vivo

  1994cited by this paper
• Regulation of IgE and IgG4 responses by allergen specific T-cell clones to bee venom phospholipase A2 in vitro.

  1994cited by this paper
• Position Paper: Immunotherapy with Hymenoptera venoms

  1993cited by this paper
• Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals

  1993influential reference
• Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production.

  1993cited by this paper
• Rapid Hymenoptera venom immunotherapy: comparative safety of three protocols

  1993cited by this paper
• IL-10 and viral IL-10 prevent IL-4-induced IgE synthesis by inhibiting the accessory cell function of monocytes.

  1993cited by this paper
• Soluble CD40 ligand can replace the normal T cell-derived CD40 ligand signal to B cells in T cell-dependent activation

  1993cited by this paper
• Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice

  1993cited by this paper
• Human peripheral blood basophils primed by interleukin 3 (IL-3) produce IL-4 in response to immunoglobulin E receptor stimulation

  1993cited by this paper
• Immunotherapy with aluminum hydroxide adsorbed insect venom extracts (Alutard SQ): immunologic and clinical results of a prospective study over 3 years

  1993cited by this paper
• T cell epitope specificity in human allergic and nonallergic subjects to bee venom phospholipase A2.

  1993cited by this paper
• Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells.

  1993cited by this paper
• Position paper: Immunotherapy with hymenoptera venoms. (EAACI) The European Academy of Allergology and Clinical Immunology.

  1993cited by this paper
• Control of allergic reactivity in human filariasis. Predominant localization of blocking antibody to the IgG4 subclass.

  1992cited by this paper
• Differential effects of IL-4 and IL-10 on IL-2-induced IFN-gamma synthesis and lymphokine-activated killer activity.

  1992cited by this paper
• IL-10 inhibits mitogen-induced T cell proliferation by selectively inhibiting macrophage costimulatory function.

  1992cited by this paper
• T cell subsets and their soluble products regulate eosinophilia in allergic and nonallergic asthma.

  1991cited by this paper
• Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity.

  1991cited by this paper
• Anti-CD40 monoclonal antibodies or CD4+ T cell clones and IL-4 induce IgG4 and IgE switching in purified human B cells via different signaling pathways.

  1991cited by this paper
• IL-10 inhibits cytokine production by activated macrophages.

  1991cited by this paper
• Changes in nasal metachromatic cells during allergen immunotherapy

  1991cited by this paper
• Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes

  1991cited by this paper
• High gradient magnetic cell separation with MACS.

  1990cited by this paper
• Antigenic structure of the hexacosapeptide melittin: evidence for three determinants, one with a helical conformation.

  1989cited by this paper
• Regulation of human basophil mediator release by cytokines. I. Interaction with antiinflammatory steroids.

  1989cited by this paper
• Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones

  1989cited by this paper
• The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients.

  1988cited by this paper
• IL-4 is an essential factor for the IgE synthesis induced in vitro by human T cell clones and their supernatants.

  1988cited by this paper
• Seasonal asthma in northern California: allergic causes and efficacy of immunotherapy.

  1986cited by this paper
• Evaluation of decline in serum venom-specific IgE as a criterion for stopping venom immunotherapy.

  1986cited by this paper
• Nasal challenge with ragweed pollen in hay fever patients. Effect of immunotherapy.

  1985cited by this paper
• Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response.

  1983cited by this paper
• Generation of antigen-specific suppressor cells during allergy desensitization.

  1980cited by this paper
• A controlled trial of immunotherapy in insect hypersensitivity.

  1978cited by this paper
• Allergy to insect stings. II. Phospholipase A: the major allergen in honeybee venom.

  1976cited by this paper
• A case for venom treatment in anaphylactic sensitivity to hymenoptera sting.

  1974cited by this paper
• Diagnosis and treatment of insect sensitivity.

  1966cited by this paper

• Recombinant Hypoallergenic Cat Allergy Vaccines

  2025cites this paper
• The importance of IgG N-glycosylation in Health, Disease, and Neonatal hemochromatosis

  2025cites this paper
• Trends and hotspots on hymenoptera venom immunotherapy: a bibliometric and visualized analysis of research from 2014 to 2024

  2025cites this paper
• Patients’ perspective on allergen immunotherapy for respiratory allergy

  2025cites this paper
• Vaccination contre les allergies : immunothérapie spécifique des allergènes

  2024cites this paper
• Natural killer T cells in allergic asthma: implications for the development of novel immunotherapeutical strategies

  2024cites this paper
• The Combination of Allergen Immunotherapy and Biologics for Inhalant Allergies: Exploring the Synergy.

  2024cites this paper
• IgE versus IgG and IgA: Differential roles of allergen‐specific antibodies in sensitization, tolerization, and treatment of allergies

  2024cites this paper
• Long-term tolerance and efficacy of venom immunotherapy after an episode of Crohn’s disease and ankylosing spondylitis after up-dosing

  2024cites this paper
• The Role of Regulatory B Lymphocytes in Allergic Diseases

  2024cites this paper
• Evaluation of the Cytokine Response Induced by Specific Allergen Immunotherapy in Patients with Vespa velutina Anaphylaxis

  2024cites this paper
• The role of regulatory B cells in immune regulation and childhood allergic asthma

  2024cites this paper
• Alteration of Immunoregulatory Patterns and Survival Advantage of Key Cell Types in Food Allergic Children

  2023cites this paper
• Mechanism underlying polyvalent IgG-induced regulatory T cell activation and its clinical application: Anti-idiotypic regulatory T cell theory for immune tolerance

  2023cites this paper
• Mechanisms of Allergen Immunotherapy and Potential Biomarkers for Clinical Evaluation

  2023cites this paper
• Hot topics in allergen immunotherapy, 2023: Current status and future perspective

  2023cites this paper
• TH1/TH2 repolarization in induction of immune tolerance to non-steroidal anti-inflammatory drugs during the management of sickle cell disease vaso-occlusive crisis.

  2023cites this paper
• Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper

  2023cites this paper
• Increase in the prevalence of follicular regulatory T cells correlates with clinical efficacy of sublingual immunotherapy with house dust mites

  2023cites this paper
• Peptide immunotherapy for aeroallergens.

  2023cites this paper
• Allergy: Mechanistic insights into new methods of prevention and therapy

  2023cites this paper
• Updates and Recent Advances on Venom Immunotherapy

  2023cites this paper
• The epithelial barrier: The gateway to allergic, autoimmune, and metabolic diseases and chronic neuropsychiatric conditions.

  2023cites this paper
• Regulatory T Cell-Targeted Immunomodulatory Therapy for Long-Term Clinical Improvement of Atopic Dermatitis: Hypotheses and Perspectives

  2023cites this paper
• Der p 1-specific Treg and Breg cells in allergen immunotherapy and mechanism of immune tolerance

  2023cites this paper
• The Roots and Growth of Allergen Immunotherapy

  2023cites this paper
• Vaccination against infectious agents and allergen-specific immunotherapy: A critical analysis

  2023cites this paper
• Olive-Derived Antioxidant Dietary Fiber Modulates Gut Microbiota Composition and Attenuates Atopic Dermatitis Like Inflammation in Mice.

  2023cites this paper
• Legends of allergy and immunology: Kurt Blaser and major contributions to deciphering the role of T cells in allergic disease

  2023cites this paper
• Ceratonia siliqua pods (Carob) methanol extract alleviates doxorubicin-induced nephrotoxicity via antioxidant, anti-inflammatory and anti-apoptotic pathways in rats

  2023cites this paper
• Allergen immunotherapy: progress and future outlook

  2023cites this paper
• Allergen immunotherapy: past, present and future

  2022cites this paper
• How the Immune System Responds to Allergy Immunotherapy

  2022cites this paper
• Allergen immunotherapy for long-term tolerance and prevention.

  2022cites this paper
• Features of B Cell Responses Relevant to Allergic Disease

  2022cites this paper
• Human Cytomegalovirus pUL11, a CD45 Ligand, Disrupts CD4 T Cell Control of Viral Spread in Epithelial Cells

  2022cites this paper
• Mechanisms and biomarkers of successful allergen-specific immunotherapy

  2022cites this paper
• Accelerated/rush allergen immunotherapy.

  2022cites this paper
• Therapeutic Potential of Bee and Scorpion Venom Phospholipase A2 (PLA2): A Narrative Review

  2022cites this paper
• Immunological changes during desensitization with cow's milk: how differ from natural tolerance or nonallergic state?

  2022cites this paper
• Immunotherapies in the treatment of immunoglobulin E‑mediated allergy: Challenges and scope for innovation (Review).

  2022cites this paper
• Allergen immunotherapy for allergic airway diseases: Use lessons from the past to design a brighter future.

  2022cites this paper
• Circulating C-X-C Motif Ligand 13 as a Biomarker for Early Predicting Efficacy of Subcutaneous Immunotherapy in Children With Chronic Allergic Rhinitis

  2022cites this paper
• Allergen immunotherapy, cancer, and immune disorders

  2022cites this paper
• B-cell targeted therapies in pemphigus

  2021cites this paper
• The Therapeutic Effect of Traditional LiuJunZi Decoction on Ovalbumin-Induced Asthma in Balb/C Mice

  2021cites this paper
• One hundred and ten years of Allergen Immunotherapy: A journey from empiric observation to evidence

  2021cites this paper
• IL‐10 induces IgG4 production in NOD‐scid Il2rγnull mice humanized by engraftment of peripheral blood mononuclear cells

  2021cites this paper
• The role of allergen‐specific IgE, IgG and IgA in allergic disease

  2021cites this paper
• The role of IgE, IgG, and IgA in tolerance, sensitization, and targeted treatment of allergic disease

  2021cites this paper
• Regulatory and IgE+ B Cells in Allergic Asthma.

  2021cites this paper
• Interleukin 10 and transforming growth factor-beta 1 plasma levels in atopic dogs before and during immunotherapy.

  2021cites this paper
• Hymenoptera Venom Immunotherapy: Immune Mechanisms of Induced Protection and Tolerance

  2021cites this paper
• ANTIVIRAL EFFECT OF THE EGYPTIAN BEE VENOM (BV) AND ITS FRACTION (PLA2) ON INFLUENZA VIRUS: IN-VITRO STUDY

  2020cites this paper
• Regulatory B cells control airway hyperreactivity and lung remodeling in a murine asthma model.

  2020cites this paper
• Biology and dynamics of B cells in the context of IgE‐mediated food allergy

  2020cites this paper
• Regulatory T cell and cytokine changes in children undergoing 3 days rush venom immunotherapy.

  2020cites this paper
• B-cell targeted therapies in pemphigus.

  2020cites this paper
• Mechanisms of Subcutaneous and Sublingual Aeroallergen Immunotherapy: What Is New?

  2020cites this paper
• Specificity of the T Cell Response to Protein Biopharmaceuticals

  2020cites this paper
• Regulatory T cell therapy: Current and future design perspectives.

  2020cites this paper
• The effect of hymenoptera venom immunotherapy on neutrophils, interleukin 8 (IL-8) and interleukin 17 (IL-17).

  2020cites this paper
• Multi-faceted regulation of IgE production and humoral memory formation.

  2020cites this paper
• The role of Treg cell subsets in allergic disease.

  2020cites this paper
• Prevention, Diagnosis and Treatment of Food Allergy:

  2020cites this paper
• Venom immunotherapy in Europe and the United States

  2020cites this paper
• Thoracic Involvement in IgG4-Related Disease

  2020cites this paper
• Mechanisms of allergen-specific immunotherapy for allergic rhinitis and food allergies

  2020cites this paper
• Role of Regulatory T Lymphocytes in Health and Disease

  2020cites this paper
• The role of regulatory T cells in allergic rhinitis and their correlation with IL-10, IL-17 and neopterin levels in serum and nasal lavage fluid

  2020cites this paper
• Systems and Synthetic Immunology

  2020cites this paper
• A20-OVA Nanoparticles Inhibit Allergic Asthma in a Murine Model

  2020cites this paper
• Sublingual dendritic cells targeting by aptamer: Possible approach for improvement of sublingual immunotherapy efficacy.

  2020cites this paper
• Tryptophan metabolite-regulated Treg responses contribute to attenuation of airway inflammation during specific immunotherapy in a mouse asthma model

  2020cites this paper
• Venom immunotherapy in Europe and the United States

  2020cites this paper
• Mechanisms of allergen-specific immunotherapy and allergen tolerance.

  2020cites this paper
• IL-10 und TGF-β1 Plasmaspiegel bei atopischen Hunden vor und während der Immunotherapie

  2020cites this paper
• B regulatory cells in allergy

  2020cites this paper
• Mechanisms of Allergen Immunotherapy in Allergic Rhinitis

  2020cites this paper
• Night shift work and immune response to the meningococcal conjugate vaccine in healthy workers: a proof of concept study.

  2020cites this paper
• Understanding of the Molecular Mechanisms of Allergy.

  2019cites this paper
• Measurement of Specific IgG Anti-Fel d 1 Antibodies.

  2019cites this paper
• The association of allergic sensitization patterns in early childhood with disease manifestations and immunological reactivity at 10 years of age

  2019cites this paper
• Der p 1‐specific regulatory T‐cell response during house dust mite allergen immunotherapy

  2019cites this paper
• Role of Der p 1–specific B cells in immune tolerance during 2 years of house dust mite–specific immunotherapy

  2019cites this paper
• Food allergen-specific sublingual immunotherapy modulates peripheral T cell responses of dogs with adverse food reactions.

  2019cites this paper
• Unravelling the apoptotic mechanisms in T-lymphocytes in an animal model for pollen induced airway allergy and studying the impact of specific immunotherapy.

  2019cites this paper
• B Regulatory Cells in Autoimmunity

  2019cites this paper
• Investigating cytokine biomarkers as early predictors of poor clinical outcome following major trauma

  2019cites this paper
• New Strategies for Prevention and Treatment of Insect Bite Hypersensitivity in Horses

  2019cites this paper
• Il-10 producing T and B cells in allergy.

  2019cites this paper
• Hymenoptera Venom Allergy: Management of Children and Adults in Clinical Practice.

  2019cites this paper
• Allergy

  2019cites this paper
• Hymenoptera Venom Allergy: How Does Venom Immunotherapy Prevent Anaphylaxis From Bee and Wasp Stings?

  2019cites this paper
• T cell epitopes of Per a 10 modulate local-systemic immune responses and airway inflammation by augmenting Th1 and T regulatory cell functions in murine model.

  2019cites this paper
• B-cell responses in allergen immunotherapy.

  2019cites this paper
• Anti-human CD63 monoclonal antibody COS3A upregulates monocyte-induced IL-10 excretion leading to diminution of CD3-mediated T cell response.

  2019cites this paper
• Pegvaliase: Immunological profile and recommendations for the clinical management of hypersensitivity reactions in patients with phenylketonuria treated with this enzyme substitution therapy.

  2019cites this paper
• IL‐10 mRNA levels in whole blood cells correlate with house dust mite allergen immunotherapy efficacy

  2019cites this paper
• Bee Venom Immunotherapy: Current Status and Future Directions

  2019cites this paper